- Location
dasatinib
"-
Adding Cancer Drug Dasatinib to Therapy May Slow Progression of Advanced Breast Cancer
Dec 26, 2013Adding the cancer drug dasatinib to standard hormone therapy may slow the progression of advanced breast cancer, a preliminary study suggests. The drug, sold under the name Sprycel, is already approved in the United States for chronic ...
Tags: cancer drug, dasatinib, hormone therapy, advanced breast cancer
-
The UK NICE Has Rejected Pfizer's New Chronic Myeloid Leukaemia (CML) Drug
Jul 17, 2013The UK National Institute for Health and Care Excellence (NICE) has rejected Pfizer’s new chronic myeloid leukaemia (CML) drug, Bosulif (bosutinib). NICE chief executive Sir Andrew Dillon said there is evidence to suggest that ...
Tags: Cancer Drug, Medicine
-
EC Granted Conditional Marketing Authorization for Bosutinib Anti-Cancer Drug in The EC
Apr 1, 2013The European Commission (EC) has granted conditional marketing authorization for Pfizer's Bosulif (bosutinib) anti-cancer drug in the European Union (EU). Bosulif is authorized in Europe for the treatment of adult patients with chronic ...
Tags: Pfizer Bosulif, cancer drug, drug
-
Teva Pharmaceutical Received US FDA Approval for Synribo Injection
Nov 28, 2012Teva Pharmaceutical has received US Food and Drug Administration(FDA)approval for Synribo injection to treat adult patients with chronic phase(CP)or accelerated phase(AP)chronic myeloid leukemia(CML)with resistance and/or intolerance to ...
Tags: Teva Synribo Injection, US FDA, Teva Pharmaceutical, chronic phase
Related Products
-
Dasatinib Monohydrate 863127-77-9
-
99% Dasatinib Anhydrous Powder CAS 302962-49-8 Antineoplastic Dasatinib
-
Vanzpharm API Dasatinib Powder CAS 302962-49-8
-
Anti Cancer API Dasatinib Monohydrate Powder CAS 863127-77-9
-
Dasatinib Monohydrate 863127-77-9
-
Buy 99% Pure Dasatinib Powder CAS 302962-49-8 Dasatinib
